Skip to main content

What Biogen's Quarter ended Sep 30, 2026 10-Q says: 4 signals

Biogen filed its latest 10-Q with the SEC on Oct 28, 2026. It discusses acquisition completed, compliance burden and debt refinancing.

Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.
Filed
Oct 28, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
12

Source: Autobound Signal API · 74 signals tracked for Biogen · updated

10-Q · latest 10

What Biogen's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 4 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 4 signals

    SEC EDGAR

Showing 10 of 12 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Biogen earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
LEQEMBI iClick outpacing Kisunla launch uptake by sixfoldBiogen reported that early commercial launch uptake for LEQEMBI iClick is outpacing IV administration by 3.5x and rival Alzheimer's therapy Kisunla by 6x. The subcutaneous formulation is attracting new prescribers who had never previously written an anti-amyloid therapy.
Targeting $250M run rate synergies from Apellis integrationBiogen has accelerated cost synergy identification following its Apellis acquisition, remaining on track to realize $250 million in run-rate synergies by the end of 2027. Operating dilution in 2026 is already negligible, with the transaction expected to be accretive to non-GAAP diluted EPS in 2027.
Part D formulary restrictions reduce VUMERITY revenue 11%VUMERITY revenue fell 11% year over year to $192 million due to tighter formulary management by payers under Medicare Part D post-IRA. Biogen anticipates these macro reimbursement pressures to persist across Part D drugs through the remainder of the year.
Rebuilding early research pipeline targeting 20 clinical programsBiogen completed an overhaul of its research and early development organization, delivering 5 INDs in a single year after a three-year drought. Top leadership aims to scale the early-stage portfolio to at least 20 active programs over the next few years.
Advancing clinical pipeline partnership with Stoke in DravetBiogen is actively partnering with Stoke Therapeutics to report registrational Phase 3 clinical data for zorubunursen in Dravet syndrome, expected in Q3 2027. The company is evaluating an addressable market opportunity of at least $1 billion outside the US.
Deploying predictive AI tools to identify rare disease patientsBiogen has implemented AI predictive models and commercial patient-finding tools to locate rare disease patients for SKYCLARYS. The company attributes improved conversion and efficiency to these digital tools across field operations.

Signal API · MCP

Track Biogen with the Signal API

One POST /v1/companies/enrich call with biogen.com returns Biogen 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Biogen 10-Q

When did Biogen file its latest 10-Q?
Biogen filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 28, 2026. The one before it was filed on Jul 29, 2026.
What did Biogen disclose in its latest 10-Q?
From the filing dated Oct 28, 2026: Completed $225M acquisition of RayThera Inc. on August 6, 2026
What did Biogen say on its recent earnings calls?
Q3 FY2026: LEQEMBI iClick outpacing Kisunla launch uptake by sixfold (dated Oct 28, 2026).
Where can I read Biogen's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →